X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CIPLA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CIPLA AUROBINDO PHARMA/
CIPLA
 
P/E (TTM) x 16.0 44.6 35.9% View Chart
P/BV x 4.1 3.9 105.7% View Chart
Dividend Yield % 0.4 0.3 115.0%  

Financials

 AUROBINDO PHARMA   CIPLA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
CIPLA
Mar-17
AUROBINDO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs895622 143.9%   
Low Rs622458 135.7%   
Sales per share (Unadj.) Rs254.6181.9 140.0%  
Earnings per share (Unadj.) Rs39.312.9 305.2%  
Cash flow per share (Unadj.) Rs46.629.3 158.9%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.30.4 89.0%  
Book value per share (Unadj.) Rs160.0155.7 102.7%  
Shares outstanding (eoy) m585.88804.51 72.8%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.03.0 100.3%   
Avg P/E ratio x19.342.0 46.0%  
P/CF ratio (eoy) x16.318.4 88.4%  
Price / Book Value ratio x4.73.5 136.7%  
Dividend payout %6.415.5 41.0%   
Avg Mkt Cap Rs m444,390434,516 102.3%   
No. of employees `00014.023.0 60.7%   
Total wages/salary Rs m17,67826,338 67.1%   
Avg. sales/employee Rs Th10,667.86,349.1 168.0%   
Avg. wages/employee Rs Th1,264.31,143.0 110.6%   
Avg. net profit/employee Rs Th1,645.8449.3 366.3%   
INCOME DATA
Net Sales Rs m149,157146,302 102.0%  
Other income Rs m1,1592,287 50.7%   
Total revenues Rs m150,316148,589 101.2%   
Gross profit Rs m34,34324,758 138.7%  
Depreciation Rs m4,27613,229 32.3%   
Interest Rs m6671,594 41.9%   
Profit before tax Rs m30,55812,222 250.0%   
Minority Interest Rs m500-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5971,798 422.6%   
Profit after tax Rs m23,01210,354 222.2%  
Gross profit margin %23.016.9 136.1%  
Effective tax rate %24.914.7 169.0%   
Net profit margin %15.47.1 218.0%  
BALANCE SHEET DATA
Current assets Rs m92,06287,370 105.4%   
Current liabilities Rs m66,22333,081 200.2%   
Net working cap to sales %17.337.1 46.7%  
Current ratio x1.42.6 52.6%  
Inventory Days Days10687 121.9%  
Debtors Days Days6862 108.6%  
Net fixed assets Rs m62,919111,567 56.4%   
Share capital Rs m5861,609 36.4%   
"Free" reserves Rs m93,133123,645 75.3%   
Net worth Rs m93,719125,254 74.8%   
Long term debt Rs m1,81436,454 5.0%   
Total assets Rs m162,494209,532 77.6%  
Interest coverage x46.88.7 539.9%   
Debt to equity ratio x00.3 6.7%  
Sales to assets ratio x0.90.7 131.5%   
Return on assets %14.65.7 255.6%  
Return on equity %24.68.3 297.0%  
Return on capital %32.78.5 385.1%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m75,83851,066 148.5%   
Fx outflow Rs m30,22417,678 171.0%   
Net fx Rs m45,61333,388 136.6%   
CASH FLOW
From Operations Rs m32,78623,824 137.6%  
From Investments Rs m-17,870-13,127 136.1%  
From Financial Activity Rs m-19,153-13,239 144.7%  
Net Cashflow Rs m-4,239-2,478 171.1%  

Share Holding

Indian Promoters % 54.1 16.0 338.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.0 12.2 65.2%  
FIIs % 27.7 23.7 116.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.2 26.2 38.9%  
Shareholders   69,601 161,166 43.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - WYETH LTD COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS